A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site
- 1 November 2002
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 83 (11) , 2683-2692
- https://doi.org/10.1099/0022-1317-83-11-2683
Abstract
Both influenza A virus surface glycoproteins, the haemagglutinin (HA) and neuraminidase (NA), interact with neuraminic acid-containing receptors. The influenza virus A/Charlottesville/31/95 (H1N1) has shown a substantially reduced sensitivity to NA inhibitor compared with the A/WSN/33 (H1N1) isolate by plaque-reduction assays in Madin–Darby canine kidney (MDCK) cells. However, there was no difference in drug sensitivity in an NA inhibition assay. The replacement of the HA gene of A/WSN/33 with the HA gene of A/Charlottesville/31/95 led to a drastic reduction in sensitivity of A/WSN/33 to NA inhibitor in MDCK cells. Passage of A/Charlottesville/31/95 in cell culture in the presence of an NA inhibitor resulted in the emergence of mutant viruses (delNA) whose genomes lacked the coding capacity for the NA active site. The delNA mutants were plaque-to-plaque purified and further characterized. The delNA-31 mutant produced appreciable yields (∼106 p.f.u./ml) in MDCK cell culture supernatants in the absence of viral or bacterial NA activity. Sequence analysis of the delNA mutant genome revealed no compensatory substitutions in the HA or other genes compared with the wild-type. Our data indicate that sialylation of the oligosaccharide chains in the vicinity of the HA receptor-binding site of A/Charlottesville/31/95 virus reduces the HA binding efficiency and thus serves as a compensatory mechanism for the loss of NA activity. Hyperglycosylation of HA is common in influenza A viruses circulating in humans and has the potential to reduce virus sensitivity to NA inhibitors.Keywords
This publication has 26 references indexed in Scilit:
- Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant VariantsAntimicrobial Agents and Chemotherapy, 2001
- Adaptation of Influenza A Viruses to Cells Expressing Low Levels of Sialic Acid Leads to Loss of Neuraminidase ActivityJournal of Virology, 2001
- Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with OseltamivirThe Journal of Infectious Diseases, 2001
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences, 2000
- Influenza virus neuraminidase inhibitorsThe Lancet, 2000
- Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human InfluenzaJAMA, 1999
- Genetic Analysis Reveals That Both Haemagglutinin and Neuraminidase Determine the Sensitivity of Naturally Occurring Avian Influenza Viruses to Zanamivir in VitroVirology, 1999
- The Interaction of Neuraminidase and Hemagglutinin Mutations in Influenza Virus in Resistance to 4-Guanidino-Neu5Ac2enVirology, 1998
- Replication of Influenza A Viruses in a Green Monkey Kidney Continuous Cell Line (Vero)The Journal of Infectious Diseases, 1995
- Influenza virus neuraminidase: Structure, antibodies, and inhibitorsProtein Science, 1994